Key result
Subtype-selective antagonists and receptor knockout/knockdown have helped identify which P2Y subtypes are functionally expressed in vascular smooth muscle and endothelial cells and their mediated effects.
Why the study?
Vascular P2Y receptors mediate many effects, but the role of individual subtypes is often unclear.
This review highlights the roles of specific vascular P2Y receptor subtypes in regulating vascular tone and their potential as therapeutic targets for cardiovascular diseases like atherosclerosis and hypertension.
Subtype identification in vascular cells supports targeted P2Y research; leaves open clinical translation for hypertension or atherosclerosis.
Vascular P2Y receptors mediate many effects, but the role of individual subtypes is often unclear. Here we discuss how subtype-selective antagonists and receptor knockout/knockdown have helped identify these roles in numerous species and vessels. P2Y 1 receptor-mediated vasoconstriction and endothelium-dependent vasodilation have been characterised using the selective antagonists, MRS2179 and MRS2216, whilst AR-C118925XX, a P2Y 2 receptor antagonist, reduced endothelium-dependent relaxation, and signalling evoked by UTP or fluid shear stress. P2Y 2 receptor knockdown reduced endothelial signalling and endothelial P2Y 2 receptor knockout produced hypertensive mice and abolished vasodilation elicited by an increase in flow. UTP-evoked vasoconstriction was also blocked by AR-C118925XX, but the effects of P2Y 2 receptor knockout were complex. No P2Y 4 receptor antagonists are available and P2Y 4 knockout did not affect the vascular actions of UTP and UDP. The P2Y 6 receptor antagonist, MRS2578, identified endothelial P2Y 6 receptors mediating vasodilation, but receptor knockout had complex effects. MRS2578 also inhibited, and P2Y 6 knockout abolished, contractions evoked by UDP. P2Y 6 receptors contribute to the myogenic tone induced by a stepped increase in vascular perfusion pressure and possibly to the development of atherosclerosis. The P2Y 11 receptor antagonists, NF157 and NF340, inhibited ATP-evoked signalling in human endothelial cells. Vasoconstriction mediated by P2Y 12 /P2Y 13 and P2Y 14 receptors was characterised using the antagonists, cangrelor, ticagrelor, AR-C67085 and MRS2211 or PPTN respectively. This has yet to be backed up by receptor knockout experiments. Thus, subtype-selective antagonists and receptor knockout/knockdown have helped identify which P2Y subtypes are functionally expressed in vascular smooth muscle and endothelial cells and the effects that they mediate.
No takes yet. Share an insight, caveat, or question.
Dales et al. (2024) conducted a review in Vascular P2Y receptor function. Selective antagonists and genetic modification was evaluated. Subtype-selective antagonists and receptor knockout/knockdown have helped identify which P2Y subtypes are functionally expressed in vascular smooth muscle and endothelial cells and their mediated effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: